NT-3/TrkC Axis Contributes to the Perineural Invasion and the Poor Prognosis in Human Salivary Adenoid Cystic Carcinoma.
NT-3
Schwann cells
TrkC
perineural invasion
salivary adenoid cystic carcinoma
Journal
Journal of Cancer
ISSN: 1837-9664
Titre abrégé: J Cancer
Pays: Australia
ID NLM: 101535920
Informations de publication
Date de publication:
2019
2019
Historique:
received:
29
01
2019
accepted:
25
08
2019
entrez:
26
11
2019
pubmed:
26
11
2019
medline:
26
11
2019
Statut:
epublish
Résumé
The present study was aimed to investigate the role and mechanism of neurotrophin-3 (NT-3) and its specific receptor tropomyosin receptor kinase C (TrkC) in the perineural invasion (PNI) process of the salivary adenoid cystic carcinoma (SACC). The co-cultured system between SACC cells and Schwann cells (SCs) was employed to detect the expression of NT-3 and TrkC. The results of ELISA, qRT-PCR and western blot showed that NT-3 was noticeably elevated in the co-cultured SACC-83 cells, while TrkC was increased in the co-cultured SCs. The results of scratch wound healing, migration, and 3D co-culture assays showed that the directional migration abilities of the co-cultured SACC-83 cells and SCs were significantly increased. Under the stimulation of NT-3, the directional motor ability of SACC-83 cells and SCs was significantly improved, and the apoptosis of SACC-83 cells and SCs were obviously inhibited. In addition, blocking TrkC by its specific inhibitor AZD7451 could significantly inhibit these effects. Immunohistochemistry staining showed that the positive expression of NT-3 (88.5%) and TrkC (92.3%) was significantly correlated with the PNI in SACC specimens (
Identifiants
pubmed: 31762816
doi: 10.7150/jca.33635
pii: jcav10p6065
pmc: PMC6856580
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6065-6073Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
J Pathol. 1997 Apr;181(4):405-12
pubmed: 9196438
Lab Chip. 2010 Jul 7;10(13):1671-7
pubmed: 20414488
Clin Cancer Res. 2016 Apr 15;22(8):2083-95
pubmed: 27084744
Prostate. 2000 Oct 1;45(2):140-8
pubmed: 11027413
Mol Clin Oncol. 2014 Sep;2(5):725-730
pubmed: 25054037
Head Neck. 2014 Jul;36(7):998-1004
pubmed: 23784851
Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8774-9
pubmed: 15161978
Cancer Immunol Immunother. 2017 Aug;66(8):959-968
pubmed: 27885383
JAMA Oncol. 2017 Feb 1;3(2):244-255
pubmed: 27442865
Handb Clin Neurol. 2013;115:55-79
pubmed: 23931775
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14421-6
pubmed: 14614136
J Control Release. 2018 Jan 28;270:246-259
pubmed: 29233763
Nature. 1990 Oct 25;347(6295):762-5
pubmed: 2172829
Oncogene. 2013 Aug 29;32(35):4064-77
pubmed: 23001042
PLoS Genet. 2013;9(7):e1003552
pubmed: 23874207
J Invest Dermatol. 2008 Aug;128(8):2031-40
pubmed: 18305571
Int J Biochem Cell Biol. 2006;38(12):1995-9
pubmed: 16807057
J Neurochem. 2012 Aug;122(3):501-11
pubmed: 22607199
PLoS Biol. 2004 Dec;2(12):e403
pubmed: 15550985
Int J Oral Maxillofac Surg. 2010 Mar;39(3):235-42
pubmed: 19951834
Oncol Rep. 2014 Feb;31(2):800-6
pubmed: 24337063
Curr Opin Otolaryngol Head Neck Surg. 2017 Apr;25(2):147-153
pubmed: 28106659
Nat Rev Cancer. 2016 Jun;16(6):399-408
pubmed: 27150016
J Natl Cancer Inst. 2014 Aug 08;106(8):null
pubmed: 25106646
Oncogene. 2013 Aug 8;32(32):3698-710
pubmed: 23027130
Oncol Rep. 2016 Jan;35(1):427-35
pubmed: 26530352
Head Neck. 2015 Jul;37(7):1038-45
pubmed: 24710845
Int J Cancer. 1999 May 5;81(3):417-27
pubmed: 10209957